- Home
- CAPL vs TYRA Comparison
CAPL vs TYRA Comparison
Compare CAPL & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPL
- TYRA
- Stock Information
- Founded
- CAPL 1992
- TYRA 2018
- Country
- CAPL United States
- TYRA United States
- Employees
- CAPL N/A
- TYRA N/A
- Industry
- CAPL Oil Refining/Marketing
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- CAPL Energy
- TYRA Health Care
- Exchange
- CAPL Nasdaq
- TYRA Nasdaq
- Market Cap
- CAPL 793.6M
- TYRA 667.3M
- IPO Year
- CAPL 2012
- TYRA 2021
- Fundamental
- Price
- CAPL $21.34
- TYRA $12.15
- Analyst Decision
- CAPL
- TYRA Strong Buy
- Analyst Count
- CAPL 0
- TYRA 8
- Target Price
- CAPL N/A
- TYRA $31.00
- AVG Volume (30 Days)
- CAPL 24.6K
- TYRA 235.4K
- Earning Date
- CAPL 11-05-2025
- TYRA 11-06-2025
- Dividend Yield
- CAPL 9.84%
- TYRA N/A
- EPS Growth
- CAPL 100.77
- TYRA N/A
- EPS
- CAPL 1.13
- TYRA N/A
- Revenue
- CAPL $3,522,840,000.00
- TYRA N/A
- Revenue This Year
- CAPL N/A
- TYRA N/A
- Revenue Next Year
- CAPL N/A
- TYRA N/A
- P/E Ratio
- CAPL $18.95
- TYRA N/A
- Revenue Growth
- CAPL N/A
- TYRA N/A
- 52 Week Low
- CAPL $19.50
- TYRA $6.42
- 52 Week High
- CAPL $25.73
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- CAPL 59.90
- TYRA 53.82
- Support Level
- CAPL $20.25
- TYRA $11.82
- Resistance Level
- CAPL $20.67
- TYRA $12.80
- Average True Range (ATR)
- CAPL 0.48
- TYRA 0.67
- MACD
- CAPL 0.07
- TYRA -0.06
- Stochastic Oscillator
- CAPL 94.40
- TYRA 29.08
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.